Q-omics provides the consensus-scored DMRTC1B profile across patient tissues and cancer cell-line models. DMRTC1B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, DMRTC1B is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, DMRTC1B RNA expression shows 11,218 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, KIRC, and TGCT as cancer lineages where DMRTC1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DMRTC1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DMRTC1B survival associations across molecular data types. DMRTC1B RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DMRTC1B RNA expression–survival associations across cancer types. High DMRTC1B expression shows unfavorable associations in UCEC, ACC, LIHC and TGCT, but favorable associations in ESCA and KIRP. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCEC as the clearest survival context for DMRTC1B RNA expression.
This table summarizes DMRTC1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DMRTC1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DMRTC1B shows lower tumor expression in KIRC, THCA, READ, UCEC, BRCA and LUSC. The KIRC box plot shows higher DMRTC1B RNA expression in normal versus tumor tissue (log2 FC = −0.051, t-test p < 0.001).
This table shows molecular features associated with DMRTC1B in patient tissues and cancer cell lines. In patient samples, DMRTC1B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, DMRTC1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
